Founded in 1999,  Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox.  The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development.

    * High-throughput ADME screening
    * Customised ADME assays
    * In silico ADME predictive modeling
    * In vitro toxicology

Life Sciences

Cyprotex

Cyprotex's headquarters in Macclesfield, United Kingdom

The Watertown office focuses on scientific research and study management, supporting innovation and business development.

People (12)

Jobs (0)

Other offices